TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance

Intercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling

(2019) Jiao Wu et al.   NATURE

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

(2019) Alessandro Leonetti et al.   BRITISH JOURNAL OF CANCER

BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells

(2019) David N. Debruyne et al.   NATURE

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies

(2018) Zheng-Hai Tang et al.   CANCER LETTERS

Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors

(2018) Cecilia Lopez Sambrooks et al.   CANCER RESEARCH

Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial–mesenchymal transition phenotype

(2018) Jing Xu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Toosendanin, a natural product, inhibited TGF-β1-induced epithelial-mesenchymal transition through ERK/Snail pathway

(2018) Weiwei Luo et al.   PHYTOTHERAPY RESEARCH

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma

(2018) Chee Khoon Lee et al.   JAMA Oncology

CD44 facilitates epithelial to mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer

(2018) Kenichi Suda et al.   MOLECULAR CANCER THERAPEUTICS

Nagilactone E suppresses TGF-β1-induced epithelial–mesenchymal transition, migration and invasion in non-small cell lung cancer cells

(2018) Le-Le Zhang et al.   PHYTOMEDICINE

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

(2018) Zofia Piotrowska et al.   Cancer Discovery

Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma

(2018) Mau-Ern Poh et al.   Journal of Thoracic Disease

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

(2018) Geoffrey R. Oxnard et al.   JAMA Oncology

Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer

(2018) Pei-Chih Lee et al.   CANCER CELL

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

(2018) Khyati N. Shah et al.   NATURE MEDICINE

New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer

(2018) Anushka Dongre et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

(2017) Matthew J. Hangauer et al.   NATURE

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

(2017) Vasanthi S. Viswanathan et al.   NATURE

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

NF-kappaB Is Involved in the Regulation of EMT Genes in Breast Cancer Cells

(2017) Bruno R. B. Pires et al.   PLoS One

Epithelial–mesenchymal transition: a new target in anticancer drug discovery

(2016) Fabrizio Marcucci et al.   NATURE REVIEWS DRUG DISCOVERY

NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance

(2016) Ching-Feng Chiu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming

(2016) Praveena S. Thiagarajan et al.   Oncotarget

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line

(2016) Zheng-Hai Tang et al.   Oncotarget

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

(2015) Matthew G Oser et al.   LANCET ONCOLOGY

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

(2015) Xiaofeng Zheng et al.   NATURE

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance

(2015) Kari R. Fischer et al.   NATURE

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

(2015) Matthew J. Niederst et al.   Nature Communications

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

(2015) Collin M. Blakely et al.   Cell Reports

Targeting molecular addictions in cancer

(2014) I Vivanco   BRITISH JOURNAL OF CANCER

Molecular mechanisms of epithelial–mesenchymal transition

(2014) Samy Lamouille et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells

(2013) Masakuni Serizawa et al.   Journal of Thoracic Oncology

The complexity of NF-κB signaling in inflammation and cancer

(2013) Bastian Hoesel et al.   Molecular Cancer

A Correction to the Research Article Titled: "Inositol Polyphosphate Multikinase Is a Coactivator of p53-Mediated Transcription and Cell Death" by R. Xu, N. Sen, B. D. Paul, A. M. Snowman, F. Rao, M. S. Vandiver, J. Xu, S. H. Snyder

(2013)   Science Signaling

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

(2011) Trever G. Bivona et al.   NATURE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Shared Principles in NF-κB Signaling

(2008) Matthew S. Hayden et al.   CELL